When Clinical Data Contradicts Your Marketing Claims
Three weeks before submission, the clinical evaluation report lands on the regulatory desk. The conclusion is clear: the available clinical data does not support two of the five performance claims in the Instructions for Use. The marketing team says the claims have been in use for years. The Notified Body expects alignment. Someone has to resolve this, and no one wants to be the one who delays the submission.
In This Article
This situation happens more often than manufacturers want to admit. Marketing claims evolve over time. They get refined in sales presentations, adapted for different markets, and adjusted to highlight competitive advantages. Meanwhile, clinical evaluation remains anchored in what can actually be demonstrated with data.
When these two paths diverge, the gap becomes a regulatory risk. It is not just about wording. It is about whether the device can be placed on the market at all.
Where the Divergence Starts
Marketing claims are often written early in the product development cycle. At that stage, the clinical strategy might still be forming. The claims reflect intended performance, anticipated outcomes, or what the engineering team believes the device will deliver.
Then the clinical evaluation begins. Data is collected. Literature is searched. Equivalence is assessed. Post-market data is reviewed.
And sometimes, the data does not fully align with what was promised.
The contradiction is not always dramatic. It can be subtle. A claim states that the device “significantly reduces recovery time,” but the clinical data shows a trend without statistical significance. Another claim says the device is “suitable for patients with severe symptoms,” but the studies only included moderate cases.
Manufacturers assume that if a claim has been used in a previous device generation or in marketing materials for years, it is automatically supported. This assumption collapses during Notified Body review when the clinical evaluation does not substantiate the claim.
The problem is not that marketing was dishonest. The problem is that no one checked whether the clinical evidence kept pace with the messaging.
Why This Matters Under MDR
Under MDR Article 61 and Annex I, the manufacturer must demonstrate that the device achieves its intended performance. This is not optional. It is a conformity requirement.
Section 1 of Annex I states that devices must be designed and manufactured in such a way that they are suitable for their intended purpose. Section 3 requires that the device achieves the performance intended by the manufacturer.
If the Instructions for Use claim a specific clinical benefit, and the clinical evaluation report does not support that benefit, the device does not meet the General Safety and Performance Requirements. The Notified Body cannot issue a certificate.
MDCG 2020-5 on Clinical Evaluation reinforces this. It explains that clinical data must be sufficient to demonstrate that the device performs as intended and that the benefit-risk profile is acceptable. Claims made in labeling and promotional materials must be reflected in the clinical evidence.
When there is a mismatch, the Notified Body will issue a deficiency. The manufacturer must either provide additional data to support the claim, or revise the claim to match the available evidence.
The Notified Body does not care what the marketing department promised. They care what the clinical evaluation demonstrates. If the data does not support the claim, the claim must change.
How Manufacturers Try to Fix This
When the contradiction surfaces, manufacturers typically take one of three approaches. Not all of them work.
Approach 1: Revise the Clinical Evaluation to Support the Claim
The first instinct is to search for more data. Perhaps there is a study that was missed. Perhaps the literature search was too narrow. Perhaps post-market data from another region can fill the gap.
This approach works if the data actually exists and is relevant. But often, it does not. The claim was based on an assumption, not on evidence. Going back to find supporting studies rarely produces what is needed.
I have seen manufacturers spend months searching for data to justify a claim, only to realize that the clinical evidence simply does not support it. The time would have been better spent revising the claim.
Approach 2: Reinterpret the Existing Data
Another strategy is to reframe the clinical evaluation so that the existing data appears to support the claim. This involves creative interpretation of endpoints, selective citation of study results, or broad extrapolation from limited data.
This is dangerous. Notified Body reviewers are trained to spot overinterpretation. If the clinical data shows a non-significant trend, calling it “evidence of benefit” will trigger a deficiency. If the study population does not match the intended use, claiming equivalence will not stand.
Reinterpretation might satisfy an internal review, but it will not survive external scrutiny.
Manufacturers try to use post-market surveillance data to retroactively justify claims that were never clinically validated. PMS data is valuable, but it cannot replace a proper clinical evaluation at the time of submission.
Approach 3: Revise the Marketing Claims
The third option is the most straightforward. Adjust the claims in the Instructions for Use, labeling, and promotional materials to match what the clinical data actually demonstrates.
This is often met with resistance. Marketing teams worry about competitive positioning. Sales teams fear losing key messages. Leadership sees it as a step backward.
But from a regulatory perspective, this is the only reliable solution when the data does not support the claim.
It does not mean the device is ineffective. It means the claim must be accurate.
How to Resolve the Contradiction
The resolution process requires coordination between clinical affairs, regulatory affairs, and marketing. Here is how it should work in practice.
Step 1: Conduct a Claim-by-Claim Audit
List every performance claim in the Instructions for Use, promotional materials, and technical documentation. For each claim, identify the corresponding evidence in the clinical evaluation report.
Ask: Does the clinical data directly support this statement? Is the evidence sufficient, relevant, and current?
If the answer is no, mark the claim as unsupported.
This audit should happen early, ideally before the technical file is finalized. Waiting until Notified Body review to discover the gap is costly.
Step 2: Assess the Data Gap
For each unsupported claim, determine whether additional clinical data can reasonably be obtained.
Can a post-market clinical follow-up study generate the missing evidence? Is there a published study that was overlooked? Can equivalence be established to a device with supporting data?
If the answer is yes, define a plan to generate or obtain the data. If the answer is no, the claim must be revised.
Do not assume that a PMCF study will solve the problem. PMCF is for ongoing evaluation, not for addressing fundamental gaps in pre-market evidence. If the claim cannot be supported now, it should not be made now.
Step 3: Revise the Claims or the Clinical Strategy
If the data exists, update the clinical evaluation report to reference it properly. Ensure the appraisal is clear and the conclusions are explicit.
If the data does not exist, revise the claim. Make it more conservative. Remove superlatives. Focus on what can be demonstrated.
For example, instead of “significantly reduces recovery time,” write “supports recovery according to clinical data.” Instead of “suitable for severe cases,” write “intended for moderate to severe cases as per study population.”
This is not marketing defeat. It is regulatory compliance.
Step 4: Align All Documentation
Once the claims are revised, update every document that references them. This includes the Instructions for Use, labeling, promotional materials, risk management file, and clinical evaluation report.
Do not leave inconsistencies. If the IFU says one thing and the CER says another, the Notified Body will notice.
Step 5: Communicate the Change Internally
Explain to the commercial teams why the change was made. Frame it as risk mitigation, not as a limitation. Make it clear that unsupported claims expose the company to regulatory action, market withdrawals, and reputational damage.
Most commercial teams understand this once the regulatory risk is explained clearly.
What Happens If You Do Not Resolve It
Ignoring the contradiction does not make it disappear. It makes it a deficiency.
The Notified Body will identify the mismatch during their review. They will issue a finding. The manufacturer will have to respond, either by providing additional evidence or revising the claim.
If the response is inadequate, the certificate will be delayed or denied.
If the device is already on the market, the contradiction becomes a post-market surveillance issue. Competent authorities can request justification. If the manufacturer cannot provide it, corrective action may be required. In serious cases, the device may be recalled.
Manufacturers assume that if the Notified Body did not catch the issue during initial certification, it is acceptable. Post-market surveillance and vigilance audits often reveal these gaps later, with more serious consequences.
Prevention Is Easier Than Correction
The best time to align clinical data with marketing claims is before the claims are finalized. This requires early collaboration between clinical affairs and marketing.
When a new claim is proposed, ask immediately: What clinical evidence supports this? Is that evidence sufficient under MDR? If not, what is the plan to generate it?
If the evidence does not exist and cannot be generated before market entry, do not make the claim.
This discipline prevents the contradiction from forming in the first place.
It also reduces the risk of costly delays, rejected submissions, and post-market corrections.
Final Thought
Clinical data and marketing claims must tell the same story. When they diverge, the clinical data wins. Not because regulators are rigid, but because patient safety depends on accurate representation of device performance.
The manufacturers who understand this early avoid the painful reconciliation process later. They design their clinical strategy and their commercial messaging together, with the same evidence base supporting both.
When the clinical evaluation report lands on the regulatory desk, there are no surprises. The claims are supported. The submission moves forward.
That alignment is not luck. It is planning.
Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report).
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
– Regulation (EU) 2017/745 (MDR), Annex I, General Safety and Performance Requirements
– MDR Article 61, Clinical Evaluation
– MDCG 2020-5, Clinical Evaluation Assessment Report Template
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
